

Final EIS for the Programmatic Development Plan and Phase I Implementation prepared by GSA in September 2001.

A public meeting will be held to determine the significant issues related to development of the new Census Bureau building and the long-term use of the Suitland Federal Center. The meeting will serve as part of the formal environmental review/scoping process for the preparation of the EA. It is important that Federal, regional, state, county and local agencies, and interested individuals and groups take this opportunity to identify environmental concerns that should be addressed during preparation of the EA. The public and review agencies are also encouraged to submit written comments on the potential impacts of the proposed Census Bureau development plan. Public comments received will be considered for determining the issues to be assessed in the environmental document. The public and review agencies are encouraged to provide additional comments once the EA is released.

The public scoping meeting will be held: Wednesday, May 1st at 7 p.m. at the Suitland Federal Center, Community Room, 4211 Suitland Road, Suitland, Maryland.

Adequate signs will be posted on the building to direct meeting participants. The meeting will begin with a brief presentation of the project and the environmental impact assessment process. After the presentation, GSA representatives will be available to receive comments from the public regarding issues of concern and the scope of the EA. In the interest of available time, each speaker will be asked to limit oral comments to five minutes.

Agencies and the general public are invited and encouraged to provide written comments on the scoping issues in addition to, or in lieu of, oral comments at the public meeting. To be most helpful, environmental review/scoping comments should clearly describe specific issues or topics that the community believes the EA should address. All written comments regarding the proposed project must be postmarked no later than May 12, 2002 to: General Services Administration, Attn: Mr. Jag Bhargava, Project Executive, Capital Development Division, 7th and D Streets, SW., Room 2110, Washington, DC 20407.

For further information please contact: Mr. Jag Bhargava, General Services Administration (202-708-6944) E-mail: [jag.bhargava@gsa.gov](mailto:jag.bhargava@gsa.gov)

Dated: April 8, 2002.

**Jag Bhargava,**

*Project Executive.*

[FR Doc. 02-8976 Filed 4-12-02; 8:45 am]

**BILLING CODE 6820-14-M**

## GENERAL SERVICES ADMINISTRATION

### [GSA Bulletin FMR B-3]

#### Motor Vehicle Management

This notice contains GSA Bulletin FMR B-3 which addresses the use of tobacco products in motor vehicles owned or leased by the Federal Government. The text of the bulletin follows:

To: Heads of Federal Agencies.

Subject: Use of Tobacco Products in Motor Vehicles Owned or Leased by the Federal Government.

1. *What is the purpose of this bulletin?* This bulletin provides guidance to Executive agencies concerning the use of tobacco products in motor vehicles owned or leased by the Federal government. Other Federal agencies are also encouraged to consider this guidance.

2. *What is the effective date of this bulletin?* This bulletin is effective April 15, 2002.

3. *When does this bulletin expire?* This bulletin will remain in effect until specifically cancelled.

4. *What is the background?*

a. In 1993, the General Services Administration (GSA) Fleet Program prohibited the use of tobacco products in GSA Fleet vehicles because of the potential health hazards associated with the use of these products and the negative residual effects of tobacco use on GSA Fleet vehicles.

b. The Federal Fleet Policy Council (FEDFLEET) comprised of national level Federal agency fleet managers requested GSA's Office of Governmentwide Policy, Federal Vehicle Policy Division (MTV) to develop a recommendation regarding the use of tobacco products in motor vehicles owned or leased by the Federal government. Many agencies already prohibit the use of tobacco products in their vehicles; therefore, FEDFLEET recommended a policy that would apply to the entire Federal fleet.

5. *What is the recommended policy we are encouraged to follow when issuing guidance on the use of tobacco products in motor vehicles owned or leased by the Federal government?*

Agencies are encouraged to:

a. Prohibit the use of tobacco products in motor vehicles owned or leased by the Agency.

b. Begin discussions with employee unions and organizations if required by union agreements to prohibit the use of tobacco products in such motor vehicles.

c. Develop appropriate policy regarding disciplinary action to be taken against employees violating this prohibition.

6. *Who should we contact for further information and/or to direct comments regarding the issue of prohibiting the use of tobacco products in motor vehicles owned or leased by the Federal government?*

General Services Administration, Office of Governmentwide Policy, Federal Vehicle Policy Division (MTV), Washington, DC 20405, Telephone Number: 202-501-1777, E-mail Address: [vehicle.policy@gsa.gov](mailto:vehicle.policy@gsa.gov).

Dated: April 8, 2002.

**G. Martin Wagner,**

*Associate Administrator, Office of Governmentwide Policy.*

[FR Doc. 02-9003 Filed 4-12-02; 8:45 am]

**BILLING CODE 6820-14-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Notice of Meetings: Secretary's Advisory Committee on Genetic Testing

Pursuant to Public Law 92-463, notice is hereby given of two meetings of the Secretary's Advisory Committee on Genetic Testing (SACGT), U.S. Public Health Service. An education conference, *Genetic Testing and Public Policy: Preparing Health Professionals*, will be held from 8:30 a.m. to 5 p.m. on May 13, 2002. SACGT's thirteenth meeting will be held from 9 a.m. to 5:30 p.m. on May 14, 2002 and 8 a.m. to 2:30 p.m. on May 15, 2002. Both meetings will be held at the Hyatt Regency, 300 Light Street, Baltimore, MD and are free and open to the public with attendance limited to space available. Pre-registration is encouraged for the May 13 education conference. Online registration for the May 13 conference is available at <http://www4.od.nih.gov/oba/sacgt.htm> or by calling Abbe Smith at 301-897-7423. A catered luncheon is offered on May 13 at a cost of \$30 and requires advance registration.

The one-day education conference will consider the challenges of integrating genetic testing into clinical and public health practice for the wide range of health professionals likely to be affected by this expanding field.

Through a combination of plenary presentations and panel discussions, the conference will explore the integration of genetics into primary care and discuss the various roles of healthcare providers in the provision of genetics services. Afternoon focus groups will concentrate on several different areas of genetics education, training, and integration. Conference participants will be asked to consider a number of public policy questions of interest to SACGT, including how are health professions schools responding to changes and challenges brought about by genetics and genetic testing; are future health professionals being taught what they need to know to integrate new health technologies and services into the clinical and public health settings; are current health professionals, who were trained long before the explosion of genetics knowledge, receiving the training they need to continue to practice effectively; are they being taught about the proper use and interpretation of genetic tests and about their ethical, legal, and social implications; are the revolutionary advances in genetics having an equally revolutionary effect on our educational methods; what changes are already underway; are they sufficient; are they occurring quickly enough; is government doing as much as it should do? On the following day during its regular Committee meeting, SACGT will consider these issues and develop its recommendations to the Secretary.

Reviewing the outcomes of the SACGT Education Conference will be the Committee's first order of business at its May 14–15 meeting. In addition, four of the SACGT work groups will be presenting reports to the Committee: The ACCESS Work Group will present a draft report on billing and reimbursement for genetic education and counseling services; the Informed Consent/Institutional Review Board Work Group will present its revised recommendations on decision making and informed consent for clinical and public health genetic tests; the Data Work Group will present three case studies on the development and clinical application of a genetic test; and the Rare Disease Work Group will present a report on genetic testing for rare diseases. Presentations will also be made on the development of a "Frequently Asked Questions" document on Clinical Laboratory Improvement Amendments certification and the Food and Drug Administration's progress in the development in the development of a pre-market review of genetic tests. Time will be provided for

public comment and interested individuals should notify the contact person listed below.

Under authority of 42 U.S.C. 217a, Section 222 of the Public Health Service Act, as amended, the Department of Health and Human Services established SACGT to advise and make recommendations to the Secretary through the Assistant Secretary for Health on all aspects of the development and use of genetic tests. SACGT is directed to (1) recommend policies and procedures for the safe and effective incorporation of genetic technologies into health care; (2) assess the effectiveness of existing and future measures for oversight of genetic tests; and (3) identify research needs related to the Committee's purview.

The draft meeting agenda and other information about SACGT will be available at the following Web site: <http://www4.od.nih.gov/oba/sacgt/htm>. Individuals who wish to provide public comment or who plan to attend the meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the SACGT Executive Secretary, Ms. Sarah Carr, by telephone at 301-496-9838 or e-mail at [sc112@nih.gov](mailto:sc112@nih.gov). The SACGT office is located at 6705 Rockledge Drive, Suite 750, Bethesda, Maryland 20892.

Dated: April 5, 2002.

**Sarah Carr,**

*Executive Secretary, Secretary's Advisory Committee on Genetic Testing.*

[FR Doc. 02-9092 Filed 4-12-02; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Action Plan To Assure the Appropriate Use of Therapeutic Agents in the Elderly: Notice of Opportunity for Public Comment

**AGENCY:** Department of Health and Human Services, Office of the Secretary, Office of Public Health and Science, Office of Disease Prevention and Health Promotion.

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services (DHHS) solicits written comments on the key elements of a national action plan to assure the appropriate use of therapeutic agents in the elderly.

**DATES:** Written comments may be submitted on or before 5:00 p.m. E.S.T. on May 22, 2002.

**ADDRESSES:** Written comments should be sent to Debra C. Nichols, M.D.,

M.P.H., DHHS Office of Disease Prevention and Health Promotion, Office of Public Health and Science, room 738-G, 200 Independence Ave., SW., Washington, DC 20201, (202) 205-4872 (telephone), 202-205-9478 (facsimile). Comments also may be submitted electronically to [dnichols@osophs.dhhs.gov](mailto:dnichols@osophs.dhhs.gov).

#### FOR FURTHER INFORMATION CONTACT:

Debra Nichols, M.D., M.P.H. DHHS Office of Disease Prevention and Health Promotion, Office of Public Health and Science, room 738-G, 200 Independence Ave., SW., Washington, DC 20201, (202) 205-4872.

#### SUPPLEMENTARY INFORMATION:

##### Background

The Elderly are at increased risk of complications from the effects of therapeutic agents. These risks are caused by the use of multiple, concurrent medications, the use of inappropriate medication and the underuse of needed medication.

Management of this problem will require the coordinated efforts of both federal and private sectors. Provider behavior must be modified through education, the use of monitoring systems and patient and caregiver empowerment. The most important strategies that the nation can use to fight this problem must be identified.

##### Written Comments

In preparation for the development of a national action plan to assure the appropriate use of therapeutic agents in the elderly in the United States, comments are welcome from all interested stakeholders.

Comments will be most useful if they include the following information:

(1) What you consider to be the three to five most important priorities for assuring the appropriate use of therapeutic agents in the elderly in the United States.

(2) How, as a nation, we should pursue these strategies.

(3) Your views on the most effective ways to address disparities among different segments of the population.

(4) (If applicable) A short summary of activities that your organization is engaged in or plans to engage in to assure the appropriate use of therapeutic agents in the elderly. Submitted information may become part of a publicly accessible website information center, or be otherwise made available.